Tyra Biosciences is a Carlsbad, California-based company discovering and developing new small molecule therapies targeting acquired resistance in oncology. Its core focus is developing very specific compounds aimed at drug-resistant cancer cells and populations. The company was incubated by Alta Partners and is led by co-founder and CEO Todd Harris and co-founder and COO Daniel Bensen. The team includes senior scientific and operational staff and several scientific advisors, reflecting a purpose-built founding team optimized for tackling acquired resistance. Tyra intends to use recent funding to advance next-generation compounds toward clinical trials. The company emphasized developing agents that address resistance to current therapies.

Total raised

$50M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2020